https://www.live-feeds.com/feed/failure-of-novartis-lp-a-drug-raises-questions-about-cardiovascular-strategyContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/failure-of-novartis-lp-a-drug-raises-questions-about-cardiovascular-strategyhttps://www.live-feeds.com/feed/failure-of-novartis-lp-a-drug-raises-questions-about-cardiovascular-strategy#u195409Thu, 12 Nov 2026 00:43:28 +0000Novartis has discontinued development of pelacarsen, its lipoprotein(a)-lowering antisense drug, after the Phase 3 Lp(a)HORIZON trial showed no reduction in major cardiovascular events versus placebo despite significantly lowering Lp(a) levels. The trial enrolled patients with established cardiovascular disease and elevated Lp(a). Full results presented at the American Heart Association meeting on November 7 confirmed the lack of benefit in secondary prevention. This follows a similar setback for Novo Nordisk's ziltivekimab, another inflammation-targeting cardiovascular candidate, leaving